Montreal, Quebec--(Newsfile Corp. - December 15, 2025) - Quantum eMotion Corp. (TSXV: QNC) (OTCQB: QNCCF) (FSE: 34Q0) ("QeM"), a Canadian provider of quantum-safe cybersecurity technologies, announces its integration into Kirq, a quantum communication testbed developed by Numana. The collaboration supports QeM's ongoing research, testing, and validation of quantum-safe cybersecurity technologies within a collaborative testing environment.The Kirq testbed provides an infrastructure for participating organiz ...

Core Insights - The article discusses the emerging potential of quantum computing as an investment opportunity, contrasting it with traditional tech investments focused on semiconductors and cloud computing [1][2] - D-Wave Quantum is highlighted as a unique player in the quantum computing space, utilizing a different approach known as quantum annealing, which may offer advantages in optimization applications [3][5][6] Company Overview - D-Wave Quantum has a market capitalization of $9.1 billion and a current stock price of $26.10, with a gross margin of 82.82% [3] - The company reported $24 million in sales but is facing significant annual losses of nearly $400 million, raising concerns about its financial sustainability [9] Technology and Approach - D-Wave's quantum annealing method is distinct from competitors like IonQ and Rigetti, which use trapped ion and superconducting qubits respectively [4][5] - The technology is primarily exploratory and lacks meaningful commercial applications at this stage, focusing on niche services [3][4] Market Position and Risks - D-Wave's approach may be less purpose-built compared to its peers, potentially limiting its commercial adoption if quantum annealing is less effective at scale [8] - The company's price-to-sales ratio of 331 is significantly higher than historical tech stock valuations, indicating a speculative investment environment [11] Leadership and Investor Sentiment - Concerns are raised about the confidence of D-Wave's leadership, as several executives have sold shares while the company issued stock at premium valuations [12] - The article suggests that D-Wave is a speculative stock, cautioning average retail investors to avoid it and leave trading to risk-seeking individuals [13]

Core Viewpoint - Rigetti Computing has seen a significant stock price increase, but D-Wave Quantum may present a more favorable investment opportunity due to its stronger recent performance and commercialization potential in quantum computing [1][4][9]. Company Performance - Rigetti Computing's stock price has surged approximately 300% over the past year and around 2,540% over the last three years [1]. - In the third quarter, Rigetti's revenue declined 18% year over year to about $1.95 million, with total sales for the first nine months of the year at $5.22 million, down from $8.52 million in the same period last year [5]. - D-Wave Quantum reported third-quarter sales of $3.7 million, representing a 100% increase, and total revenue of $15.3 million for the first nine months, reflecting a growth of 235% [5]. Technology and Market Approach - Rigetti Computing is focused on long-term technological advancements in quantum computing, which may yield better payoffs but is considered more speculative [4][9]. - D-Wave Quantum employs a quantum-annealing approach that appears to offer better near-term commercialization opportunities, leading to more rapid sales growth [4][8]. Future Outlook - Rigetti's growth trajectory is uncertain, hinging on the success of its less developed quantum technologies and partnerships [7]. - D-Wave's recent sales gains are seen as indicative of a more promising growth trajectory, supported by its focus on quantum-annealing technology [8].

Core Insights - Quantum Computing Inc. (QUBT) has significantly strengthened its financial position through aggressive capital strategies, increasing cash and equivalents to $352.4 million and investments to $460.6 million, resulting in total liquidity of approximately $813 million, followed by an oversubscribed $750 million private placement, pushing liquid assets above $1.5 billion [1][8] - The substantial capital raises validate institutional investors' confidence, allowing QCi to operate with minimal debt while maintaining manageable cash burn of around $10 million per quarter [2][3] - QCi's enhanced balance sheet enables aggressive investment in R&D, scaling operations, and pursuing strategic growth opportunities without reliance on immediate revenue spikes [3][8] Peer Update - D-Wave Quantum (QBTS) reported a record cash balance of $836.2 million in Q3, a significant increase from $29.3 million in the same quarter last year, driven by warrant exercises [4] - IonQ (IONQ) reported a pro-forma cash balance of approximately $3.5 billion after a $2 billion equity offering, reflecting strong investor demand and providing liquidity for long-term commercialization and acquisitions [5] Market Performance - QUBT shares have increased by 110.4% over the past year, outperforming the industry growth of 2% and the S&P 500's 15.3% increase [6][8] - QUBT currently trades at a forward Price-to-Sales (P/S) ratio of 1955.20X, significantly higher than the industry average of 5.56X, indicating an expensive valuation [9] Earnings Estimates - The loss per share estimate for QUBT for 2025 has narrowed by 6 cents to 19 cents over the past 30 days [10]

Core Insights - The quantum computing sector is gaining attention, with significant stock price increases for companies like IonQ, Rigetti Computing, D-Wave Quantum, and Quantum Computing Inc. over the past year, outperforming the Nasdaq Composite index [2][10] - The addressable market for quantum computing is projected to reach $1 trillion by 2035, with potential global economic value creation of up to $850 billion by 2040, attracting investor interest [3][8] - Historical trends suggest that the current enthusiasm for quantum computing stocks may lead to a bubble, with a potential downturn expected around 2026 [10][19] Company Performance - IonQ, Rigetti, D-Wave, and Quantum Computing Inc. have seen stock price increases of 43%, 545%, 458%, and 67% respectively over the past year, indicating strong market interest [2] - Rigetti Computing has a market cap of $9 billion, while IonQ's market cap stands at $19 billion, reflecting their significant positions in the market [7][14] - Despite the stock price growth, these companies are still in the early commercialization phase, with analysts suggesting practical applications of quantum computing may not be realized until the end of the decade [15][19] Market Trends - JPMorgan Chase has initiated a $1.5 trillion, 10-year investment plan that includes up to $10 billion for quantum computing, highlighting the sector's importance for national economic security [8] - The current price-to-sales (P/S) ratios for these companies are above 30, which historically indicates unsustainable valuations and potential for a market correction [17][19] - The historical pattern of overhyped technologies suggests that the quantum computing sector may face a similar fate as past trends, such as the dot-com bubble [12][19] Future Outlook - The quantum computing industry is expected to experience significant sales growth by 2026, but the sustainability of this growth is uncertain due to high valuations and competition from larger tech companies [15][20] - The first-mover advantage of current quantum computing companies may be challenged as larger firms with more resources enter the market [20]

Core Insights - Qolab has received a strategic investment from Western Digital, aiming to enhance quantum computing hardware through collaboration [1][2] - The partnership focuses on advancing nanofabrication processes to improve qubit performance, reliability, and scalability for practical quantum systems [2][4] Company Overview - Qolab is a leader in developing utility-scale superconducting quantum computers, leveraging deep physics and engineering expertise alongside semiconductor partnerships [5] Industry Impact - The collaboration strengthens U.S. leadership in semiconductor research and nanofabrication, promoting local innovation and job creation in California's technology corridor [3] - The joint effort aims to translate quantum computing from research into scalable production, aligning with Western Digital's strategy to apply engineering expertise to emerging fields like quantum computing [4]

Core Insights - TransCode Therapeutics, Inc. has announced a collaboration with Quantum Leap Healthcare Collaborative to evaluate its lead therapeutic candidate TTX-MC138 in the PRE-I-SPY clinical trial platform [1][2] Group 1: Clinical Trial Details - The PRE-I-SPY program will include TTX-MC138 in a Phase 2a dose-expansion clinical trial, enrolling up to 45 patients with colorectal cancer who are ctDNA positive after standard therapy [2][3] - The Phase 2a trial is set to begin in the first half of 2026 and will be led by Dr. Paula Pohlmann from MD Anderson Cancer Center [2] Group 2: Therapeutic Potential - The trial aims to assess the biological and clinical activity of TTX-MC138 in the Minimal Residual Disease (MRD) setting, targeting patients with a high risk of recurrence [3][4] - TTX-MC138 is designed to inhibit microRNA-10b, which is believed to play a critical role in the progression of metastatic cancers [5][6] Group 3: Company Background - TransCode Therapeutics is focused on developing immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers, with TTX-MC138 being its lead candidate [6] - The company has a portfolio of first-in-class therapeutic candidates aimed at mobilizing the immune system to combat cancer cells [6] Group 4: Collaborative Efforts - Quantum Leap Healthcare Collaborative sponsors the I-SPY Trials, which aim to rapidly screen promising treatments and identify effective therapies for specific patient subgroups [7][8] - The collaboration aims to accelerate the evaluation of TTX-MC138, with the goal of advancing effective and less toxic precision therapies into later trial phases [4][8]

Core Insights - Inturai Ventures Corp. has successfully delivered quantum-safe encryption for connected devices in defense, aged care, and home security sectors, in partnership with PQStation, holding exclusive deployment rights in these areas [1][7] - The encryption technology was tested using both post-quantum cryptography (PQC) alone and in combination with traditional security, demonstrating strong performance with low delay and minimal power impact [2] - The global ESP32 module market, crucial for billions of devices, was valued at approximately $2.1 billion in 2023 and is projected to reach $4.6 billion by 2032, indicating significant growth potential for Inturai's technology [3] Industry Context - Governments in the U.S., Canada, Australia, and the EU are mandating post-quantum security upgrades to begin by 2026, with critical sectors like defense and healthcare required to be fully transitioned by 2028 [4][7] - This global momentum towards post-quantum security highlights the urgency and relevance of Inturai's early deployment advantage in securing vital systems against emerging quantum threats [4][7] - Inturai's advancements position the company at the forefront of spatial intelligence technology, enabling secure, AI-powered sensing without heavy hardware or complexity [5]

Core Viewpoint - Quantum BioPharma Ltd. has successfully closed a non-brokered private placement, issuing 30 Class A Multiple Voting Shares at a price of $25 each, resulting in gross proceeds of $750 million [1][2]. Offering Details - The securities issued are subject to a statutory hold period of four months plus a day from issuance as per Canadian securities laws [2]. - Proceeds from the offering will be utilized for general working capital purposes [2]. Related Party Transactions - Xorax Family Trust and Fortius Research and Trading Corp., both associated with company insiders, purchased all Class A Multiple Voting Shares in the offering, qualifying as a related-party transaction under MI 61-101 [3]. - The company has relied on exemptions from formal valuation and minority shareholder approval requirements as the transaction did not exceed 25% of the company's market capitalization [3]. Corporate Update - The company has terminated its at-the-market offering agreement with H.C. Wainwright & Co., effective December 6, 2025, with the termination taking effect on December 20, 2025 [16]. - No Class B Subordinate Voting Shares have been sold under the previous sales agreement, which allowed for the sale of up to $21.225 million worth of shares [17]. Debt Settlement - Quantum BioPharma has settled $260,000 owed to an arm's length creditor by issuing 17,626 Class B Subordinate Voting Shares at a deemed price of $14.75 per share [18]. Company Overview - Quantum BioPharma focuses on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with its lead compound, Lucid-MS, aimed at preventing myelin degradation associated with multiple sclerosis [19]. - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc., which includes a royalty agreement of 7% on sales until reaching $250 million, after which the royalty will drop to 3% [19].

Core Insights - Rigetti Computing (RGTI) is planning to develop a more advanced quantum chip fabrication facility to achieve >99.9% fidelity levels necessary for commercial-grade quantum systems [1][8] - The company is exploring partnerships with existing foundries, participating in U.S. government initiatives, and considering building a new 200-300mm fab to enhance process quality and qubit consistency [2][8] Company Updates - Quantum Computing Inc. (QUBT) has launched its first commercial entangled-photon source for quantum networking and secure communications [3] - QUBT is scaling production at its photonic foundry and expanding into quantum sensing and cybersecurity, indicating a shift towards commercial deployment [4] - D-Wave Quantum (QBTS) has made its Advantage2 annealing system commercially available, featuring over 4,400 qubits and enhanced performance [5][6] Market Performance - RGTI shares have increased by 84.9% year-to-date, significantly outperforming the industry growth of 9.9% [7] - The company has a price-to-book ratio of 24.69, which is above the industry average, and carries a Value Score of F [10] - The Zacks Consensus Estimate for Rigetti's 2025 earnings indicates a projected decline of 88.9% from the previous year [13]